Podcast Host Disclosures:

Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. 

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

Bladder Cancer Canada

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Program Chair: Ricardo Rendon

Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

What is your advice for a student interested in urology? (What is Urology Series). To view the accompanying video of this audio clip please click here.

Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

Darryl Leong, MD
McMaster University

Fred Saad, MD, FRCS
CHUM, Institut de cancer de Montreal/CRCHUM

Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP
University of Montreal
Institut de cardiologie de Montreal

Sponsored by Amgen.

Luke Lavallee
Urologic Oncologist and Associate Scientist
The Ottawa Hospital
Ottawa Hospital Research Institute

Disclosures:
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

Sponsored by Amgen.

Sophie Mottard
Orthopedic Oncology Surgeon
Maisonneuve-Rosemont Hospital
CHU Saint-Justine and Santa Cabrini Hospital

Disclosures:
Payment: Amgen (conference speaker)

Sponsored by Amgen.

David Kendler
Endocrinologist and Clinical Professor
UBC

Disclosures:
Advisory Board: Amgen, Paladin, Biosynt
Speakers Bureau: Amgen
Payment: Amgen, Biosynt, Radius Pharma, Paladin
Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin
Clinical Trial: Radius Pharma
Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executive)

Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Disclosures:

Hassan Razvi
Patent: Cook Urological
Clinical Trials: Boston Scientific, Verity Pharma
Leadership/board position: AUA, Endourology Society

Olivier Traxer
Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

Ricardo Rendon
Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera
Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,
Grant/Honorarium: Astellas, Amgen, Bayer Janssen
Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

Ricardo Rendon

Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera

Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,

Grant/Honorarium: Astellas, Amgen, Bayer Janssen

Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Nimira Alimohamed
Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen

Wassim Kassouf
No disclosures

Alejandro Berlin
No disclosures

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Christian Kollmannsberger
Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer
Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer
Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Astellas, BMS, Janssen, Bayer, Merck

Disclosures:

Dean Elterman
Advisory Boards/ Speakers Bureaus: Astellas, Boston Scientific, Duchesnay, Pfizer, Procept, Prodeon, Olympus, Medtronic, Urotronic, Zeneflow

Kevin Zorn
Advisory Board: BSCI, Procept, Zenflow

Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant 

Disclosures:

Fred Saad
Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Eleni Efstathiou
Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation
Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant

The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH).

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

CUA BPH Guidelines - Google Search

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position: Kidney Cancer Canada

Luke Lavallee
Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas
Grant/Honorarium: Sanofi

Disclosures:

Derek Henderson
Banking relationship with TD

Christopher French
Advisory Boards: Astellas, AstraZeneca

Disclosures:

Martine Jolivet
Advisory Board and/or Speaker Bureau: Allergan/Abbvie

Genevieve Nadeau
Clinical Trials: Contiform International
Advisory Board and/or Speaker Bureau: Pfizer, Boston Scientific, Astellas, Allergan/Abbvie, Searchlight Pharma

Disclosures:

Kevin Carlson
Advisory Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

Disclosures:

Kevin Carlson
Advisroy Board/Payment: Abbvie

Richard Baverstock
Advisory Board: Abbvie
Speakers Bureau: Astellas, Boston Scientific, Abbvie
Payment: Abbvie, Astellas, Bsci

Greg Baily
Advisory Board/ Speaker Bureau: Abbvie

Disclosures:

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayer
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership Position: Point Biopharma

Urban Emmenegger
Advisory Boards: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Payment: Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Grant/Honorarium: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Clinical Trials: AstraZeneca, Bayer, Clovis, Janssen, Merck, Roche

Emily Thain
Advisory Boards: AstraZeneca/Merck, Pfizer
Honorarium: AstraZeneca/Merck, Pfizer

Conflits d'interests:

Fred Saad
Subventions/honoraires: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi

Zineb Hamilou
Remuneration: AstraZeneca, Sengen, EMD Serono
Essai Clinique: Sengen

Evan Weber
Subventions ou des honoraires: AstraZeneca/Merck

Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

Disclosures:

Ashley Cox
Advisory Board: Abbvie, Allergan

Rachel S. Rubin
Speakers Bureau: Sprout
Clinical Trials: Ipsen, Abbvie
Leadership/Board Position: ISSWSH

Disclosures:

Armin Aprikian
Advisory boards: Abbvie, Astellas, Bayer
Grant/Honorarium: Abbvie, Astellas, Bayer, Sanofi, TerSera

Robert Hamilton
Advisory boards: Janssen, Astellas, Bayer, TerSera
Clinical Trials: Janssen, Bayer, Astellas

Our inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com

References from the show:

UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis - PMC (nih.gov)

UBC & VGH Centre of Excellence | Vancouver Prostate Centre

Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)

Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Disclosures:

Armand Zini
Shareholder in YAD Tech - a neutraceuticals company

Jesse Ory
No disclosures

Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

Disclosures:

Girish Kilkarni
Advisory Boards: Janssen, Merck, Roche, Ferring, Astellas, Theralase
Grants/Honoraria: Abbvie, Sanofi, Ferring, TerSera, Knight Therapeutics, Verity
Clinical Trials: Merck, Astra Zeneca, Bristol Myers Squibb, Theralase, Janssen, Pfizer

Krista Noonan
Consulting/Honoraria: AstraZeneca, BMS, Janssen, Merck, Pfizer, EMD Serono
Research Support: Roche

Disclosures:  

Michael Leveridge
Ipsen - speaker session moderator 2019

Maryam Soleimani
Honorarium: Pfizer
Grant funding: Abbvie, Astellas, Bayer

Himu Lukka
No disclosures

Disclosures:  

Sebastien J. Hotte
Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem
Grants (Institution): BMS, Janssen, Bayer
Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen

Tamim Nizai
Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA

Andrea Kokorovic
No disclosures 

Delay of Injection (Q&A series)

0:00 - Ricardo Rendon

9:30 - Fred Saad

18:10 - Jasper Yuen

Podcast Host Disclosures:

Dr. Alimohamed has had a consulting or advisory role with Astellas Pharma, AstraZeneca, Janssen, Merck, Pfizer, and Sanofi Canada.

Dr. Lalani has received honoraria from Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, and TerSera; has had a consulting or advisory role with Abbvie, Astellas Pharma, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche/Genentech, and TerSera; and has received research funding from Bristol-Myers Squibb (Inst), Ipsen, Novartis, and Roche.

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

References:

Bellmunt J, et al. Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021;39(suppl 15): abstr 4532. https://bit.ly/3axehzb

Loriot Y, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348. https://www.nejm.org/doi/full/10.1056/NEJMoa1817323

O’Donnell PH, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. J Clin Oncol. 2021;39(suppl 15): abstr 4508. https://bit.ly/3gyklv5

Powles T, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. https://www.nejm.org/doi/full/10.1056/NEJMoa2035807

Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

Program Chair: Ricardo Rendon

Kidney Cancer Panelists: Melissa Huynh, Lori Wood

Sponsors:
Gold: Bristol Myers Squibb, Merck
Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Disclosures:

Daniel Heng
Consultancies and advisory boards: BMS, Merck, Pfizer, Novartis, Eisai, Exilexas, Ipsen

Anand Swaminath
Advisory board: Astrazeneca
Expert Speaker: Astrazeneca, BMS, Eisai
Grants (in kind): BMS, Roche

Rodney Breau
No disclosures

Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi 

Disclosures:

Brita Danielson
Honoraria and speakers fees: Astellas, Amgen, Bayer, Ferring, Janssen

Nazanin Fallah-Rad
Consultancy/Advisory: Merck, Ipsen, Pfizer, Nekktar therapeutics
Honorariums: Bayer, Janssen, Ipsen, Astellas, Pfizer, Merck
Travel Grants: Nekktar Therapeutics

Vincent Fradet
Consultant, speaker or research agreement: Abbvie, Amgen, Astra Zeneca, Astellas, Bayer, Ferring, Janssen, Sanofi